|
NIH/CMS Coordinating Committee for Trials and Data Sharing
|
Committee, Work group, Advisory group, or Task Force
|
CMS
|
NIDDK, NCI, NCATS, NIA
|
NIH and CMS meet periodically to discuss areas of common interest with respect to both clinical trials and research data. The lead for NIH is NCRR.
|
|
NIH/CMS Interagency Committee
|
Committee, Work group, Advisory group, or Task Force
|
CMS
|
NHLBI, NCI, NCATS, NEI, NIA, NIDDK
|
The NIH-CMS Committee is a trans-NIH committee that fosters collaboration between NIH and CMS to fulfill their respective missions.
|
|
NIH/FDA Interagency Clinical Outcome Assessments Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIA, CC, NCCAM, NCI, NHLBI, NIAMS, NICHD, NIDDK, NIMH, NINDS, OD
|
The NIH-FDA Interagency Clinical Outcome Assessments Working Group is a chartered group. The purpose of the group is for the two agencies to work together strategically to foster science and processes related to the development and application of Clinical Outcome Assessments for use in medical product development and clinical and translational research to support regulatory science.
|
|
NIH/FDA Joint Leadership Council
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
OD/OSP, NCI, NHLBI, NIAID, NIDDK, NIGMS, NIMH, NINDS, OD
|
The Joint Leadership Council will work together to help ensure that regulatory considerations form an integral component of biomedical research planning, and that the latest science is integrated into the regulatory review process. Such collaboration and integration will advance the development of new products for the treatment, diagnosis and prevention of common and rare diseases and enhance the safety, quality, and efficiency of the clinical research and medical product approval enterprise. The formation of the Leadership Council represents a commitment on the part of both agencies to forge a new partnership and to leverage the strengths of each agency toward this common goal.
|
|
NIH/FDA Leadership Council Working Group Drug Rescue & Repurposing Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID, OD
|
NIH has been working with the FDA to create the NIH-FDA Joint Leadership Council, through which senior leaders from both agencies will address ways to facilitate new processes, such as FDA review of combination therapies and its consideration of rare disease trials with fewer patients enrolled. Medicines that have been developed and approved for one indication are sometimes useful for the treatment of other diseases, leading to enormous savings in development time and costs.
|
|
NIH/FDA Tobacco Science Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIGMS, NCI
|
NIH Funding Opportunities: Research Relevant to FDA Regulatory Authority (relevant to Family Smoking Prevention and Tobacco Control Act)
|
|
Northwest Portland Tribal Registry Project
|
Resource Development
|
IHS
|
NCI
|
Over the past 10 years, health care delivery for Northwest American Indians and Alaska Natives has evolved from a centralized system maintained by the Indian Health Service (IHS) to a diverse and complex environment. The Northwest Tribal Registry Project was developed in January 1999 by the Northwest Tribal Epidemiology Center, a tribally operated program located at the Northwest Portland Area Indian Health Board (NPAIHB) in Portland, Oregon.
|
|
Nutrition Coordinating Committee (NCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA, IHS, OS
|
NIDDK, CC, CIT, CSR, FIC, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD
|
Nutrition Coordinating Committee (NCC) operates as an NIH-wide forum to review, stimulate, and encourage the support of nutrition research and training to better define the role of nutrition in the promotion and maintenance of health and in the prevention and treatment of disease. The NCC also plays a key role in the development of nutrition research policy at the NIH.
|
|
Obesity and the Built Environment Program
|
Research Initiative
|
CDC
|
NIEHS, NCI, NIDCD, OD
|
To begin understanding the wide variety of issues relating to the built environment and obesity, the NIEHS released RFA-ES-04-003, Obesity and the Built Environment, in August, 2004. Research proposals were to examine two specific areas related to the built environment and obesity: understanding the role of the built environment in causing/exacerbating obesity and related co-morbidities; and developing, implementing, and evaluating prevention/intervention strategies that influence parameters of the built environment in order to reduce the prevalence of overweight, obesity and co-morbidities. Participating NIH institutes included NCI, NICHD, and OBSSR, and two Centers within the CDC.
|
|
Offices of National Drug Control Policy (ONDCP): Colleges and Universities
|
Resource Development
|
CDC, SAMHSA
|
NIAAA
|
ONDCP supports keeping college and university students healthy through prevention, intervention, treatment, and recovery plans that effectively address the negative consequences of high risk drinking, underage drinking, and drug use on our Nation’s college and university campuses.
|